Literature DB >> 29223436

Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.

Taku Inohara1, Yohei Numasawa2, Takahiro Higashi3, Ikuko Ueda4, Masahiro Suzuki5, Kentaro Hayashida4, Shinsuke Yuasa4, Yuichiro Maekawa4, Keiichi Fukuda4, Shun Kohsaka6.   

Abstract

BACKGROUND: Percutaneous coronary intervention (PCI) is widely used; however, factors of high-cost care after PCI have not been thoroughly investigated. We sought to evaluate the in-hospital costs related to PCI and identify predictors of high costs.
METHODS: We extracted 2,354 consecutive PCI cases (1,243 acute cases, 52.8%) from 3 Japanese cardiovascular centers from 2011 to 2015. In-hospital complications were predefined under consensus definitions (eg, acute kidney injury [AKI]). We extracted the facility cost data for each patient's resource under the universal Japanese insurance system. We classified the patients into total cost quartiles and identified predictors for the highest quartile ("high-cost" group). In addition, incremental costs for procedure-related complications were calculated.
RESULTS: During the study period, a total of 401 cases (17.0%) experienced procedure-related complications. The in-hospital acute and elective PCI costs per case were US $14,840 (interquartile range [IQR] 11,370-20,070) and US $11,030 (IQR 8929-14,670), respectively. After adjusting for baseline differences, any of the procedure-related complications remained an independent predictor of high costs (acute: odds ratio 1.66, 95% CIs 1.13-2.43; elective: odds ratio 3.73, 95% CIs 1.96-7.11). Notably, incremental costs were mainly attributed to AKI, which accounted for 37.5% of all incremental costs; it increased by US $9,840 for each AKI event, and the total cost increase reached US $2,588,035.
CONCLUSIONS: Procedure-related complications, particularly postprocedural AKI, were associated with higher costs in PCI. Further studies are required to evaluate prospectively whether the preventive strategy with a personalized risk stratification for AKI could save costs.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29223436     DOI: 10.1016/j.ahj.2017.08.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Inducible pluripotent stem cell-derived mesenchymal stem cell therapy effectively protected kidney from acute ischemia-reperfusion injury.

Authors:  Sheung-Fat Ko; Yen-Ta Chen; Christopher Glenn Wallace; Kuan-Hung Chen; Pei-Hsun Sung; Ben-Chung Cheng; Tien-Hung Huang; Yi-Ling Chen; Yi-Chen Li; Hsueh-Wen Chang; Mel S Lee; Chih-Chao Yang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

2.  Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.

Authors:  Ali O Malik; Amit Amin; Kevin Kennedy; Mohammed Qintar; Ali Shafiq; Roxana Mehran; John A Spertus
Journal:  Am Heart J       Date:  2021-01-25       Impact factor: 4.749

3.  Effects of body habitus on contrast-induced acute kidney injury after percutaneous coronary intervention.

Authors:  Toshiki Kuno; Yohei Numasawa; Mitsuaki Sawano; Toshiomi Katsuki; Masaki Kodaira; Ikuko Ueda; Masahiro Suzuki; Shigetaka Noma; Koji Negishi; Shiro Ishikawa; Hiroaki Miyata; Keiichi Fukuda; Shun Kohsaka
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

4.  Cost reduction associated with transradial access in percutaneous coronary intervention: A report from a Japanese nationwide registry.

Authors:  Satoshi Shoji; Shun Kohsaka; Hiraku Kumamaru; Kyohei Yamaji; Shiori Nishimura; Hideki Ishii; Tetsuya Amano; Kiyohide Fushimi; Hiroaki Miyata; Yuji Ikari
Journal:  Lancet Reg Health West Pac       Date:  2022-08-12

5.  Exploring Triaging and Short-Term Outcomes of Early Invasive Strategy in Non-ST Segment Elevation Acute Coronary Syndrome: A Report from Japanese Multicenter Registry.

Authors:  Nobuhiro Ikemura; Yasuyuki Shiraishi; Mitsuaki Sawano; Ikuko Ueda; Yohei Numasawa; Shigetaka Noma; Masahiro Suzuki; Yukihiko Momiyama; Kentaro Hayashida; Shinsuke Yuasa; Hiroaki Miyata; Keiichi Fukuda; Shun Kohsaka
Journal:  J Clin Med       Date:  2020-04-13       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.